Novo to advance CagriSema despite missing key endpoint against Lilly in obesity trial
Patients taking CagriSema lost 23% of their body weight under the efficacy analysis, compared with 25.5% for tirzepatide
Patients taking CagriSema lost 23% of their body weight under the efficacy analysis, compared with 25.5% for tirzepatide
What's Your Reaction?
DDP Editor
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
